Actively Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Led by Jacobio Pharmaceuticals Co., Ltd. · Updated on 2026-01-22
144
Participants Needed
13
Research Sites
153 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
CONDITIONS
Official Title
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent.
- Age 18 years or older at the time of signing the informed consent form.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has received at least one line of systemic therapy for their tumor type and stage.
- Documented confirmation of TP53 Y220C mutation.
- At least one measurable lesion according to RECIST v1.1 criteria.
- Adequate blood, kidney, and liver function, and appropriate coagulation status.
- Ability to swallow and retain oral medication.
You will not qualify if you...
- Presence of active brain or spinal metastases or primary central nervous system tumor.
- Active infection requiring systemic treatment within the past 7 days.
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- Any severe or uncontrolled medical conditions.
- Left ventricular ejection fraction (LVEF) of 50% or less as assessed by ECHO or MUGA.
- Corrected QT interval by Fridericia's formula (QTcF) longer than 470 milliseconds.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Research Site
Denver, Colorado, United States, 80218
Actively Recruiting
2
Research site
Lake Mary, Florida, United States, 32771
Actively Recruiting
3
Research site
St Louis, Missouri, United States, 63110
Actively Recruiting
4
Research site
Canton, Ohio, United States, 44718
Terminated
5
Research site
Cleveland, Ohio, United States, 44195
Actively Recruiting
6
Research Site
Nashville, Tennessee, United States, 37203
Actively Recruiting
7
Research site
Houston, Texas, United States, 77030
Actively Recruiting
8
Research Site
Beijing, Beijing Municipality, China, 100000
Actively Recruiting
9
Research Site
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
10
Research Site
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
11
Research Site
Guangzhou, Guangdong, China, 510000
Not Yet Recruiting
12
Research Site
Jinan, Shandong, China, 250117
Not Yet Recruiting
13
Research Site
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
J
Jacobio Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here